A recent study found significant decreases in both hospital and payer costs and hospitalization rates for severe COPD patients post-discharge using advanced noninvasive ventilation (NIV) — specifically Philips Trilogy 100 with AVAPS-AE mode, compared to no NIV or the use of less advanced NIV therapy.
The results, announced by Royal Philips, revealed that both hospitals and payers can benefit from significant reductions in hospitalizations, readmissions and healthcare costs while also greatly improving the quality of care for patients living with COPD.
The Philips-sponsored study reviewed how hospitals and payers can more efficiently and effectively manage this COPD treatment and related comorbidities by implementing an advanced mode of NIV in the home care setting. This was reviewed in a multifaceted program that incorporates a combination of therapies including treatment using advanced NIV therapy provided by Philips Trilogy100 (AVAPS-AE modality), oxygen therapy, respiratory therapist-led care, patient education and medication reconciliation. This at-home program has now proven its potential to provide both hospitals and payers with tremendous savings while also offering the patient with treatment at home.
Key findings include:
- Hospital Savings: For a hospital covering 250 severe COPD patients, reduction of readmissions led to cumulative savings of $402,981 over 30 days and $449,101 over 90 days with a multifaceted therapy approach using Philips Trilogy in-home advanced NIV therapy versus no NIV treatment or less advanced NIV therapy devices. After examining 1,000 COPD patients being treated with this same combined treatment method using Trilogy, hospitals saved $1.6 million in the first 30 days and $1.8 million in 90 days compared to no NIV treatment or less advanced NIV therapy devices.
- Payer Savings: Payers studying admissions of 100,000 severe COPD patients had cumulative 3-year savings of $326 millionwhen using home NIV in comparison to no NIV treatment. Additionally, payers saved $1.04 billion cumulatively when using home NIV treatment compared to using a less advanced NIV therapy device over a three year period.
“The multifaceted and connected home NIV model described in this study can be easily adopted by other medical facilities and payers, and is expected to have a meaningful impact on both clinical outcomes and healthcare costs,” said Dr Teofilo Lee-Chiong, pulmonologist and Chief Medical Liaison, Philips. “As health systems continue to promote value-based care, it is increasingly important to demonstrate that programs like these can reduce costs while improving patient experiences using economic studies.”